Literature DB >> 7528607

Serum chromogranin A in the differential diagnosis of Cushing's syndrome.

F R Nobels1, W W de Herder, D J Kwekkeboom, W Coopmans, A Mulder, R Bouillon, S W Lamberts.   

Abstract

We evaluated whether measuring serum levels of chromogranin A, a marker of neuroendocrine tumours, could be useful in the differential diagnosis between pituitary, adrenal and ectopic causes of Cushing's syndrome. Thirty patients with Cushing's syndrome were studied. The localization of the tumours responsible was pituitary in 15, adrenal in 5 and ectopic in 10 patients. Serum concentrations of chromogranin A were measured in all patients. Petrosal sinus sampling for chromogranin A was performed in the cases with pituitary-dependent Cushing's syndrome. Immunohistochemical staining for chromogranin A was carried out on part of the tumour specimens. Slightly elevated serum levels of chromogranin A (range 223-262 micrograms/l) were detected in inferior petrosal sinus and peripheral venous samples from three patients with pituitary-dependent Cushing's syndrome. Serum chromogranin A showed no significant pituitary to peripheral gradient in these patients. Chromogranin A levels were not elevated in cases of adrenal Cushing's syndrome. Markedly elevated concentrations (range 270-13,900 micrograms/l) were shown in seven of 10 patients with neuroendocrine tumours with ectopic adrenocorticotrophin (ACTH) and/or corticotrophin-releasing hormone (CRH) production. Widespread metastasis was present in all these cases. Subjects with "occult" carcinoid tumours, with limited spread, had normal chromogranin A levels. Immunohistochemical staining for chromogranin A was positive in three out of five pituitary adenomas and in all neuroendocrine tumours with ectopic ACTH and/or CRH production, while it was negative in all adrenocortical tumour specimens. It is concluded that elevated serum levels of chromogranin A can serve as markers of neuroendocrine tumours with ectopic ACTH and/or CRH production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528607     DOI: 10.1530/eje.0.1310589

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

Review 2.  Carcinoid tumor of the thymus associated with Cushing's syndrome and dysgeusia: case report and review of the literature.

Authors:  Cristina Claret; Juan J Chillarón; Juana A Flores; David Benaiges; Rafael Aguiló; Mar García; Guadalupe Aguilar; Alberto Goday; Juan F Cano-Pérez
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

3.  Diagnostic accuracy of chromogranin A and calcitonin precursors measurements for the discrimination of ectopic ACTH secretion from Cushing's disease.

Authors:  Marina S Zemskova; Eric S Nylen; Nicholas J Patronas; Edward H Oldfield; Kenneth L Becker; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

4.  Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Authors:  Paweł Gut; Agata Czarnywojtek; Jakub Fischbach; Maciej Bączyk; Katarzyna Ziemnicka; Elżbieta Wrotkowska; Maria Gryczyńska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.